2022
Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.Peer-Reviewed Original ResearchConceptsSelf-reported COVID-19 infectionCOVID-19 infectionOncology meetingsEra of vaccinationCOVID-19 positivityCOVID-19 positivity ratesOncology annual meetingsPerson attendeesAmerican SocietyCOVID-19Risk of diseasePerson meetingsPositivity rateNew COVID-19 infectionsResponse rateEvent ratesSocial distancing mandates
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsConducting Goals-of-Care Discussions Takes Less Time Than Imagined.
Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky J, Egorova N, Franco R, Bickell NA. Conducting Goals-of-Care Discussions Takes Less Time Than Imagined. JCO Oncology Practice 2020, 16: e1499-e1506. PMID: 32749930, DOI: 10.1200/jop.19.00743.Peer-Reviewed Original ResearchConceptsGOC discussionsCare discussionsAdvanced solid tumor cancersDifferent hospital typesLength of encounterSolid tumor cancersTotal encounter timePatient ageAdvanced cancerHospital typeRural hospitalsMedicare coveragePatientsCancer progressionOncologistsMultivariate modelEncounter timeVisitsSignificant differencesCancerProgressionMinutesLess timeCommon misperceptionsPrognosis
2019
Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer
Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. Journal Of Geriatric Oncology 2019, 10: 669-672. PMID: 30718180, DOI: 10.1016/j.jgo.2019.01.016.Peer-Reviewed Original Research
2017
The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community
Kline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, Conway PH, Basch E. The Oncology Care Model: Perspectives From the Centers for Medicare & Medicaid Services and Participating Oncology Practices in Academia and the Community. American Society Of Clinical Oncology Educational Book 2017, 37: 460-466. PMID: 28561660, DOI: 10.1200/edbk_174909.Peer-Reviewed Original ResearchConceptsOncology Care ModelCare modelCancer care deliveryAcademic health systemMedicaid Services (CMS) Innovation CenterCancer careOncology practiceSubstantial burdenCare deliveryHealth systemUnique beneficiariesMedicaid ServicesCommunity practicePayment incentivesCareMedicareFinancial implicationsSubstantial regional differencesRegional differencesPatientsOncologists
2016
Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.
Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.Peer-Reviewed Original ResearchConceptsDay of deathLife care expendituresLife careIntensive endCancer decedentsIntensive care unit admissionCare expendituresLife care interventionsCare unit admissionEmergency department visitsSEER-Medicare databaseLast monthProportion of decedentsHospital referral regionsExpenditure differencesHospital deathICU admissionUnit admissionDepartment visitsHospice enrollmentIntensive careHighest quintileLater chemotherapyHospice useLowest quintileTrends in end-of-life cancer care in the Medicare program
Wang SY, Hall J, Pollack CE, Adelson K, Bradley EH, Long JB, Gross CP. Trends in end-of-life cancer care in the Medicare program. Journal Of Geriatric Oncology 2016, 7: 116-125. PMID: 26783015, PMCID: PMC5577563, DOI: 10.1016/j.jgo.2015.11.007.Peer-Reviewed Original ResearchConceptsLife cancer careDay of deathAggressive endLife careCancer careHospital deathHospice enrollmentEmergency departmentIntensive care unit admissionEnd Results-Medicare dataAggressiveness of endLate hospice enrollmentLife chemotherapy useCare unit admissionHospital referral regionsResult of cancerProportion of beneficiariesChemotherapy useICU admissionUnit admissionED visitsPatient demographicsTumor characteristicsReferral regionsMedicare beneficiaries
2015
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionFemaleHealth StatusHealth Status IndicatorsHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm StagingNeoplasmsOdds RatioPalliative CarePatient SelectionProportional Hazards ModelsProspective StudiesQuality of LifeRisk AssessmentRisk FactorsStress, PsychologicalSurveys and QuestionnairesTerminal CareTime FactorsTreatment OutcomeUnited StatesConceptsEnd-stage cancerGood performance statusBaseline performance statusQuality of lifeChemotherapy usePatient performance statusPerformance statusPalliative chemotherapyEastern Cooperative Oncology Group performance statusGood baseline performance statusPoor baseline performance statusProgressive metastatic cancerProgressive metastatic diseasePoor performance statusSolid tumor patientsClinical Oncology guidelinesLongitudinal cohort studyOutpatient oncology clinicsChemotherapy regimenEnd of lifeCohort studyMetastatic diseaseOncology clinicPatient survivalOncology guidelines